Rentschler Biopharma

Rentschler Biopharma

Rentschler Biopharma

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Rentschler Biopharma

Address

Erwin-Rentschler-Str. 21
88471 Laupheim, Germany

Contact

info@rentschler-biopharma.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Rentschler Biopharma

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Rentschler Biopharma last news

21/12/2023

Charles River to make Casgevy; Rentschler extends collab with 'major client'; Andelyn works with Ultragenyx

Welcome to Endpoints News' manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Charles River Laboratories said Monday it will manufacture Vertex and CRISPR Therapeutics' Casgevy, with its Memphis site having gone through audits by the FDA and EMA. CDMO RoslinCT also manufactures the gene editing therapy. CDMO Rentschler Biopharma said that it has a " major client " for its manufacturing site in Milford, MA, with the facility set to go live in the second half of next year. The manufacturer noted Wednesday it will produce its "longstanding" client's clinical-stage protein therapeutic for cancer in the US, after previously producing the same asset in Laupheim, Germany, for early-phase investigation. CDMO Andelyn Biosciences announced that it will manufacture process performance qualification batches for Ultragenyx's late-stage AAV9 gene therapy, dubbed UX111, for Sanfilippo syndrome type A. "We have successfully transferred the UX111 GMP process to our commercial manufacturing facility in Columbus, Ohio," Andelyn CCO Matt Niloff said in a Monday press release. The PPQ batches will be needed for potential future regulatory applications. CDMO Agno Pharma on Monday revealed that it will acquire the drug product formulation company Lubrizol Particle Sciences  in a deal that allows the manufacturer to absorb its drug product formulation tech and a facility in Bethlehem, PA, with about 65 staffers. CDMO Leanbio said it is allocating an additional €20 million ($22 million) to expand a facility being built near Barcelona. The site will have three production lines to produce plasmid DNA and messenger RNA, as well as recombinant proteins and antibodies, the company said Tuesday. CDMO Piramal Pharma opened the extension to its antibody-drug conjugate manufacturing site in Grangemouth, Scotland, earlier this week. The £45 million ($57 million) expansion gives the site two additional manufacturing suites on top of the first three suites. Drug container and delivery system company Schott Pharma said Tuesday that it ended its 2023 fiscal year with €899 million ($987.9 million) in revenue, which is up 9% versus €821 million ($902 million) in the previous year. On Wednesday, the company said that its new site in Jagodina, Serbia, would create more than 100 jobs. Raw material supplier Biosynth acquired chemical R&D company VIO Chemicals for an undisclosed amount, the companies revealed Tuesday.

20/12/2023

Rentschler Secures Client for New U.S. Mfg. Facility

Massachusetts facility will focus on commercial production of highly complex molecules for international clients.

20/12/2023

Rentschler Biopharma Announces Major Client Project for New U.S. Facility at Milford, MA Site

State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year LAUPHEIM, Germany and MILFORD, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the company has secured a major client for the new Rentschler Biopharma Manufacturing Center (RBMC) facility at its manufacturing site in Milford, Massachusetts. The RBMC is planned to be operational in the second half of 2024. The company, a long-standing client of Rentschler Biopharma in Germany, has contracted to have its product lead manufactured at the RBMC for clinical supply. This innovative protein therapeutic is seeking to address a form of cancer. Rentschler Biopharma successfully produced cGMP-quality product for early phase clinical testing at its manufacturing site in Laupheim, Germany. The project will now be transferred to the U.S. for additional supply. Federico Pollano, Senior Vice President Business Development of Rentschler Biopharma, said: 'We are delighted to have our client place their trust in us to manufacture their product for their continued clinical development. ... Full story available on Benzinga.com